RESUMO
Objective To investigate the expression and significance of E-cadherin and β-catenin in type Ⅰ endometrial carcinoma.Methods The expression of E-cadherin and β-catenin were detected by immunohistochemistry in 60 patients with type Ⅰ endometrial carcinoma and 10 normal endometrial tissues.The patients were followed-up postoperatively for the survival rate.Results Expression of E-cadherin and β-catenin in 10 normal endometrial tissues was all high expression,while those of both abnormal expression in type Ⅰ endometrial carcinoma with expression rates with 60.0 ％ (36/60) and 55.0 ％ (33/60),respectively,which were difference compared with both in normal endometrial tissues (P ＜ 0.05).The expression rates were markedly decreased in carcinoma with lymph node metastasis than those without lymph node metastasis.The proportions of abnormal expressions of E-cadherin and β-catenin were positively correlated with tumor grade and myometrial invasion in type Ⅰ endometrial carcinoma (P ＜ 0.05).The postoperative two-year survival rate in the patients with abnormal expression of E-cadherin and β-catenin were much lower than those with normal expression (P ＜ 0.05).Conclusions Abnormal high expression of E-cadherin and β-catenin may play important roles on generation and metastasis in type Ⅰ endometrial carcinoma.Both of them may be promising method for predicting invasion and metastasis and can be prognostic predictors in type Ⅰ endometrial carcinoma.
RESUMO
@#ObjectiveTo explore the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on acute cerebral infarction.Methods74 patients with acute cerebral infarction were divided into treatment and control groups. Two groups were treated by conventional methods of acute cerebral infarction; the treatment group was treated with rhG-CSF additionally. The two groups were measured before and 3 months after treatment by China Stroke Scale (CSS), respectively. Meanwhile, the side effect of rhG-CSF was observed during treatment.ResultsCSS score was better in the treatment group than in the control group 3 months after treatment (P＜0.05). No side effect occurred in the treatment group.ConclusionrhG-CSF is safe and effective to treat acute cerebral infarction.